Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial demonstrates that dupilumab reduces oral glucocorticoid use and exacerbations in severe asthma, indicating effective steroid-sparing therapy.
Key Points
- To assess the efficacy and safety of dupilumab in reducing oral glucocorticoid dependence and preventing severe exacerbations in patients with severe asthma.
- Interventional clinical trial (LIBERTY ASTHMA VENTURE, NCT02528214) in patients with glucocorticoid-dependent severe asthma treated with dupilumab.
- Dupilumab treatment reduced oral glucocorticoid use and decreased the rate of severe asthma exacerbations.
- Treatment with dupilumab led to clinically meaningful improvements in lung function, demonstrated by increased FEV1.
- Transient eosinophilia was observed in approximately 1 in 7 patients receiving dupilumab.
Cite This Study
Rabe et al. (2018) studied this question.